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EDITORIAL Open Access
Synovial tissue biopsy analysis: unlocking
the hidden secrets to personalised
medicine?
Helen Michelle McGettrick
Abstract
Rheumatoid arthritis is an immune-mediated
inflammatory disease of the synovium. Yet we still lack
robust tissue-specific (synovial) biomarkers that are able
to guide clinical decisions and stratify patients according
to their disease subgroup and predicted response to
treatment. The EULAR Synovitis Study Group and the
OMERACT synovial tissue biopsy (STB) Special Interests
Group have undertaken a consensus exercise to identify
factors that are important for the standardisation of STB
handling and analytical procedures in two
situations—clinical practice and translational research.
Keywords: Synovial biopsy, Rheumatoid arthritis, Synovial
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Editorial
Rheumatoid arthritis (RA) is a heterogeneous disease in
its clinical manifestations and bio-molecular pathology.
The fact that not all patients are the same makes pre-
dicting disease onset, progression and severity, and re-
sponse to treatment extremely challenging. Despite
several attempts to identify blood-based biomarkers to
guide clinical decision-making such as treatment
choices, these have generally proven to be unreliable and
inconclusive. Given the synovium is the site of disease,
have we been and are we still looking in the wrong tis-
sue? Detailed analysis of synovial tissue biopsies (STB) is
likely to reveal urgently needed, robust biomarkers that
will guide clinical decisions, and stratify patients accord-
ing to their disease subgroup and predicted response to
treatment. With this in mind, Najm and colleagues have
undertaken a consensus exercise to identify factors that
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are important for the reliability and reproducibility of
STB analysis across centres [1].
Since 1990, 1000’s of papers have been published de-
scribing phenotypic and functional abnormalities in syn-
ovial tissue from RA patients undergoing joint
replacement surgery, and more recently those having STB
at the earliest phases of disease. Thus, we have a wealth of
knowledge on the synovial tissue, but are we closer to
translating this discovery science into new biomarkers or
drugs to improve diagnosis or prognosis (e.g. response to
treatment, remission)? If we look at the story of one of my
favourite cells, the tissue-resident synovial fibroblast
(RASF): Early evidence demonstrated that RASF acquire a
highly migratory, invasive phenotype [2, 3] and they ap-
pear to display tropism for damaged tissue, migrating to
distant cell-free cartilage in vivo potentially ‘spreading’ dis-
ease [4]. Technological advances revealed epigenetic
changes imprinted into RASF contribute to their aggres-
sive phenotype (see review [5]) and that RASF themselves
are heterogeneous, existing as at least 3 functionally dis-
tinct subpopulations in the synovium [6]. More recently,
multi-cellular in vitro modelling demonstrated that syn-
ovial fibroblast communication with the blood vascular
endothelium evolves as disease progresses to shape the in-
flammatory infiltrate, and revealed the presence of transi-
tional functional phenotype in fibroblasts in the earliest
phases of disease, even before clinical diagnosis [7]. The
fibroblast journey has culminated in the identification of
an anatomically distinct ‘pathogenic’ subpopulation of syn-
ovial fibroblasts in RA patients and in murine models of
arthritis, which when injected in vivo induced a more pro-
longed and severe murine arthritis [8]. So what? Can we
translate these findings into new biomarkers and/or ther-
apies to influence clinical practice and patient outcomes?
For further information on the use of STB in drug devel-
opment see this review [9].
STB are well-tolerated by patients, with the majority will-
ing to undergo repeat biopsy [10] allowing comparative pre
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and post intervention STB analysis. Three sides of our
square are in place: clinical expertise, technology, and pa-
tient willingness. However, the fourth—standardisation in
the handling, evaluation and interpretation of STB—re-
quires considerable effort from the international rheumatol-
ogy community to reach consensus. Najm et al. have now
established a list of consensus points for standardised STB
handling and analytical procedures in two situations—clin-
ical practice and translational research [1]—and upon
which a standardisation framework can be built. This task
force used a modified Delphi analysis (structured anon-
ymised questionnaire answered independently by a panel of
experts) considering factors linked to biopsy sampling, pro-
cessing, histological criteria, immunohistochemistry ana-
lysis, STB interpretation and pathologists report for both
situation, and also RNA analysis for translational research
[1]. For the full list of items Figure 2 in Najm et al., 2018
[1], but it is worth noting that the majority of items are
identical for both clinical practice and translational re-
search. Despite this, further agreements on the minimal
area to biopsy; the quality of the STB (e.g. minimal number
of vessels, or percentage of stroma); minimal thickness of
STB sections; inclusion of CD15 as an indicator of infec-
tious arthritis; or the use of vascularity as a parameter in
clinical practice or translational research need to be
achieved [1].
On the brink of establishing international standardisa-
tion guidelines for STB handling and evaluation in clin-
ical practice and translational research, several
additional factors now need to be deliberated by the
community: the creation of a histology quality scoring
system, and its subsequent validation to reveal the rela-
tionship between the synovial immunopathology and a
patient’s response to therapy [11]. By way of example,
three major synovial phenotypes have been described
[12], with one (myeloid) associated with a good response
to TNFi treatment [13]. Beyond this, we need novel STB
biomarkers that define disease pathotype and outcome,
and that correlate with blood-based biomarkers and im-
aging techniques to provide quicker, less invasive ap-
proaches for routine clinical use and outcome measures
in clinical trials.
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